ClinicalTrials.gg
Not yet recruitingNCT07913087Updated Nov 5, 2026

Effect of Autologous Serum-Soaked Paper Patch vs. Traditional Dry Paper Patch on Tympanic Membrane Perforations

An interventional study of Autologous Serum-Soaked Paper Patch Myringoplasty and Conventional Dry Paper Patch Myringoplasty in Tympanic Membrane Perforation, sponsored by Rawalpindi Medical College. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Rawalpindi Medical College · Not applicable, Interventional, and Treatment

Updated Nov 3, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This randomized controlled trial evaluates whether an autologous serum-soaked paper patch improves complete tympanic membrane closure rates at 8 weeks compared to a traditional dry paper patch in patients with small dry tympanic membrane perforations.

Read the detailed description

Tympanic membrane perforations are a common otological condition causing conductive hearing loss and recurrent ear infections. While paper patching is a cost-effective outpatient treatment, traditional dry paper patches show inconsistent success rates. Autologous serum contains growth factors and cytokines that promote wound healing and tissue regeneration.

This single-blind, parallel-group randomized controlled trial will enroll 74 patients (37 per arm) presenting with small dry tympanic membrane perforations (≤1 quadrant, present for ≥3 months) at Rawalpindi Teaching Hospital. Following 50% trichloroacetic acid edge cautery, participants will be randomized 1:1 to receive either an autologous serum-soaked Whatman Grade 1 paper patch or a dry paper patch without using any biological agent.

The primary outcome is the rate of complete tympanic membrane closure confirmed via otomicroscopy at 8 weeks. Secondary outcomes include time to complete closure assessed during scheduled follow-up visits (Weeks 2, 4, and 8) and hearing improvement determined through pure tone audiometry.

02

Conditions studied

  • Tympanic Membrane Perforation

Keywords

  • Autologous serum
  • Paper patch myringoplasty
  • Eardrum perforation
03

In context

Tympanic Membrane Perforation

53 studies on the registry are indexed under Tympanic Membrane Perforation; 14 are open to participants now.

This study's planned enrollment of 74 is above the median of 57 across 39 interventional studies indexed under Tympanic Membrane Perforation.

Browse Tympanic Membrane Perforation studies →

Lead sponsor

Rawalpindi Medical College is the lead sponsor of 24 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-60 years.
  • Small dry tympanic membrane perforation (≤1 quadrant).
  • Dry perforation present for ≥3 months duration.
  • No active discharge or middle ear infection.
  • Conductive hearing loss confirmed on pure tone audiometry.

Exclusion criteria

Exclusion Criteria:

  • Perforation involving >1 quadrant of the tympanic membrane.
  • History of previous ear surgery.
  • Clinical or radiological evidence of cholesteatoma.
  • Ossicular chain pathology suspected clinically.
  • Uncontrolled diabetes mellitus.
  • Bleeding disorders or anticoagulant use.
  • Pregnancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Autologous Serum-Soaked Paper Patch Group

    Patients will receive an autologous serum-soaked Whatman Grade 1 paper patch applied over the tympanic membrane perforation after 50% trichloroacetic acid edge cautery.

    Procedure: Autologous Serum-Soaked Paper Patch Myringoplasty

  • Active comparator
    Traditional Dry Paper Patch Group

    Patients will receive a conventional dry Whatman Grade 1 paper patch applied over the tympanic membrane perforation after 50% trichloroacetic acid edge cautery.

    Procedure: Conventional Dry Paper Patch Myringoplasty

Interventions

  • ProcedureAutologous Serum-Soaked Paper Patch Myringoplasty

    Venous blood centrifuged at 3000 rpm for 10 minutes to harvest serum. Whatman Grade 1 filter paper is saturated with serum for 2 minutes and applied over the perforation following chemical cauterization of Tympanic Membrane margins with 50% trichloroacetic acid.

    Also known as: Myringoplasty

  • ProcedureConventional Dry Paper Patch Myringoplasty

    Sterile Whatman Grade 1 filter paper applied dry over the perforation following 50% trichloroacetic acid edge cautery.

    Also known as: Myringoplasty

06

What researchers measure

Primary outcomes

  1. Rate of Complete Closure of Tympanic Membrane Perforations

    Total absence of membrane defect on otomicroscopy, confirmed by an ENT physician masked to treatment allocation.

    Time frame: 8 weeks

Secondary outcomes

  1. Time to Complete Closure of Tympanic Membrane Perforations

    Number of days between the first patching and the first reported complete membrane re-epithelialization assessed at scheduled otomicroscopy follow-up visits.

    Time frame: Up to 8 weeks

  2. Change in Hearing Levels (Pure Tone Audiometry)

    Difference in pure tone average (air-conduction threshold at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz) before treatment and at 8 weeks, performed by a certified, treatment-masked audiologist.

    Time frame: Baseline and 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

2 registry updates since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 2 updates
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: identifiers
  2. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07913087
Lead sponsor
Rawalpindi Medical College
Responsible party
Muhammad Ali Javed (Principal Investigator, Rawalpindi Medical College) — Principal investigator
First posted
Nov 3, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Muhammad Ali Javed, MBBS
Contact
ajaved123886@gmail.com
03295718202

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion